Talk:Amylin receptor agonist
Discussion page·3 threads·no archives
This is the discussion page for the article Amylin receptor agonist. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.
Calcitonin receptor cross-activity
The article says cagrilintide engages the calcitonin receptor and that the consequence is unestablished. That is accurate but a reader may wonder why it is worth mentioning at all if nothing is known. A sentence on what calcitonin-receptor agonism does would help. — AmylinAmos (talk) 10:30, 16 April 2026 (UTC)
It is worth mentioning because it is the most obvious candidate explanation for any effect that amylin pharmacology does not predict. I will draft a sentence rather than leave it hanging. — ReceptorRhoda (talk) 14:05, 16 April 2026 (UTC)
Pramlintide uptakeResolved
"Limited uptake" is doing a lot of work. The reasons — mealtime dosing, separate injection, hypoglycaemia on initiation — are the interesting part and are now spelled out. — ClinicCorrespondent (talk) 11:15, 9 February 2026 (UTC)
The hypoglycaemia point is important and is specific to the insulin-adjunct setting rather than a property of amylin agonism itself. The wording now makes that clear. ✓ Done — HypoHildur (talk) 15:40, 9 February 2026 (UTC)
Method-coverage sentenceDone
The closing sentence of the analytical section explicitly says it is about method coverage rather than about any particular material. Good — that distinction is exactly what keeps this kind of paragraph neutral. — DisclosureDido (talk) 09:50, 20 June 2026 (UTC)
It is the formulation we settled on at Project:Sourcing guidelines and I would like to see it used consistently across the analytical sections of compound articles. ✓ Done — COA_Colwyn (talk) 13:20, 20 June 2026 (UTC)